Reports increasingly suggest that blood testing may become part of the diagnostic pathway for dementia. At the center of this development is p-tau217, a blood biomarker examined in this article.
- Biomarker
- A measurable substance or characteristic used to assess the presence or progression of a disease.
Dementia has become a society-wide concern in Japan, where the Basic Act on Dementia to Promote an Inclusive Society took effect in 20241. Alzheimer’s disease is thought to begin changing the brain long before symptoms such as memory loss appear. Until recently, detecting these invisible early changes required amyloid PET imaging or cerebrospinal-fluid analysis through lumbar puncture—tests involving substantial cost, specialized facilities, or physical burden.
- Amyloid PET imaging
- A scan using a radioactive tracer to visualize amyloid-β deposits in the brain.
p-tau217 has emerged as a blood-based indicator that may estimate Alzheimer’s-related brain pathology with high accuracy from a routine blood draw. This article explains what p-tau217 is, why it is considered important, recent developments in Japan and abroad, and the questions that remain.
What You Will Learn
- What p-tau217 is and why phosphorylation at residue 217 of the tau protein matters
- Why it is notable: diagnostic accuracy approaching PET and cerebrospinal-fluid tests and possible changes before clinical symptoms
- Recent developments, including US regulatory clearance, multicenter validation in Japanese participants, and expansion of research assays
- Future applications and unresolved challenges
What Is p-tau217?
p-tau217 refers to tau protein phosphorylated at a specific site: the 217th amino-acid residue. Measuring p-tau217 in blood plasma may indirectly indicate whether characteristic Alzheimer’s disease pathology is present in the brain. A blood draw is less invasive, simpler, and generally less costly than PET imaging or lumbar puncture, making this biomarker potentially more accessible.
- Phosphorylation
- A chemical reaction that attaches a phosphate group to a protein. It occurs normally in the body, but excessive phosphorylation of tau can contribute to pathological changes.
- Plasma
- The liquid portion of blood after blood cells have been removed.
- Minimally invasive
- Causing relatively little physical burden or tissue injury.
What Is Tau?
Tau is a protein that stabilizes microtubules, which form part of the neuronal cytoskeleton2. In a healthy state, tau supports cellular structure and transport. When it becomes excessively phosphorylated, it detaches from microtubules and can form intracellular aggregates known as neurofibrillary tangles. These tangles, together with senile plaques formed by amyloid-β, are characteristic pathological features of Alzheimer’s disease. The relationship between amyloid-β and tau is explained further in What Is Amyloid-β?.
- Microtubules
- Tubular structures that support cell shape and serve as transport tracks within neurons.
- Neurofibrillary tangles
- Fibrous aggregates formed by excessively phosphorylated tau inside neurons.
- Senile plaques
- Deposits formed by amyloid-β outside neurons in the brain.
Why Phosphorylation at Residue 217 Is Informative
Tau can be phosphorylated at several sites. Biomarkers including p-tau181 and p-tau231 have also been studied. Multiple studies have reported that phosphorylation at residue 217 correlates particularly closely with amyloid pathology in the brain and may offer greater diagnostic discrimination than markers based on other tau sites3. p-tau217 has therefore become a central focus of recent blood-biomarker research.
- Amyloid pathology
- Abnormal accumulation of amyloid-β in the brain together with associated biological changes.
Why Is p-tau217 Considered Important?
Interest in p-tau217 can be organized around two properties: accuracy and timing.
The first is diagnostic accuracy. Plasma p-tau217 may estimate brain pathology with accuracy approaching specialized PET or cerebrospinal-fluid testing. Meta-analyses combining multiple studies have found that plasma p-tau217 detects amyloid pathology with high accuracy4.
- Meta-analysis
- A statistical method that combines results from multiple studies.
The second is timing. Alzheimer’s-related pathology begins well before clinical symptoms. An international longitudinal study of families with inherited Alzheimer’s disease reported that brain changes begin more than 20 years before expected symptom onset5. Researchers are investigating whether p-tau217 begins to rise in blood during this very early phase. If so, it could help identify pathological change during the long presymptomatic period and support earlier clinical evaluation or intervention.
Recent Developments in Research and Clinical Implementation
How far have p-tau217 research and implementation progressed?
FDA Clears the First Blood Test in 2025
In May 2025, the US Food and Drug Administration cleared the first blood test intended to assist in the diagnosis of Alzheimer’s disease6. The test measures a ratio involving p-tau217 and amyloid-β42, opening the possibility of identifying amyloid plaques without relying initially on PET imaging.
The clearance applies to people aged 55 or older who show signs of cognitive decline. The test was not cleared as a screening tool for asymptomatic members of the general population.
- Screening test
- A test applied to a broad population, often without symptoms, to identify people who may have a disease or elevated risk.
Multicenter Validation in Japanese Participants
Although much of the early p-tau217 research was conducted outside Japan, validation in Japanese populations is advancing rapidly.
A study analyzing blood from 172 participants in the multicenter Japanese Alzheimer’s Disease Neuroimaging Initiative, or J-ADNI, found that plasma p-tau217 distinguished the presence or absence of brain amyloid pathology, using amyloid PET and related reference standards, with accuracy above 90%. Among people with mild cognitive impairment, those with higher p-tau217 had an approximately fivefold greater risk of developing Alzheimer’s disease during follow-up than those with lower levels7.
Accuracy Comparable to Cerebrospinal-Fluid Biomarkers and the Possibility of Fewer Invasive Tests
Commercial measurement methods have also been compared with cerebrospinal-fluid biomarkers already used clinically. An international study reported comparable diagnostic accuracy8.
In Japan, a prospective multicenter study centered on specialist memory clinics found that using a blood test as the initial step could classify approximately 40% of participants as having a low probability of brain amyloid accumulation. This result suggests that blood testing may reduce the number of PET scans and cerebrospinal-fluid tests required9.
- Prospective study
- A study that follows participants forward in time from enrollment to observe outcomes.
Expansion of p-tau217 Research Assays
Measurement technology is also moving toward broader implementation. A Japanese diagnostics manufacturer has released a research-use reagent for automated measurement of blood p-tau217 and is expanding distribution internationally, beginning in Europe10. Wider availability of standardized measurement platforms may accelerate data collection in research and drug development.
The Gray Zone in Cognitively Unimpaired People
Important uncertainties remain. Plasma p-tau217 tends to rise with aging even in some cognitively unimpaired older adults, and cases have been reported in which the blood test is positive while PET imaging is negative11. Meta-analysis also suggests that accuracy is high in people with cognitive impairment but somewhat lower in asymptomatic populations4. How to interpret p-tau217 values in people without symptoms remains an active area of research.
Use as an Outcome Measure
p-tau217 is not limited to diagnosis. Clinical trials increasingly use it as an endpoint to track biological response to treatment12, and its use is expanding in drug development and basic research.
For example, a preclinical study administered hexaraphane/6-MSITC, a compound from Japanese wasabi, to an Alzheimer’s disease mouse model. The study reported a statistically significant decline in blood p-tau217 along with changes in brain tau markers13. The findings are discussed in this NOMON & Co. article. This was animal research and does not establish an effect in humans, but it illustrates how p-tau217 is being used as a common measure in studies of both pharmaceutical and food-derived compounds.
- Preclinical study
- Research conducted in cells or animals before testing an intervention in humans.
Researchers are also beginning to combine p-tau217 with other blood markers that may reflect tau-pathology progression more directly. A two-stage approach assessing amyloid-related and tau-related processes may improve diagnostic precision further.
Expected Future Developments
More Efficient Diagnostic Pathways and Health-Economic Effects
If blood-based p-tau217 testing becomes more widely available, a diagnostic pathway that first uses blood to estimate probability could expand beyond specialist memory clinics to primary care. Restricting costly or invasive testing to people most likely to need it could reduce both patient burden and healthcare costs.
A Possible Entry Point for Earlier Intervention
Identifying pathology before symptoms could support earlier clinical assessment, review of modifiable risk factors, and treatment selection for people who meet the relevant indications. p-tau217 is therefore being studied as an entry point for a more proactive medical approach.
- Preemptive medicine
- An approach that identifies risk before disease becomes clinically apparent and intervenes early to prevent or delay onset or progression.
Remaining Challenges
Several issues require resolution. Cutoff values must be standardized across facilities and measurement platforms. Interpretation in asymptomatic individuals remains uncertain. Most importantly, p-tau217 is an aid to diagnosis; it does not establish a definitive diagnosis on its own.
Summary
- p-tau217 is a blood biomarker measuring tau phosphorylated at residue 217 and reflects Alzheimer’s-related brain pathology.
- Its diagnostic accuracy can approach that of PET and cerebrospinal-fluid testing, and research suggests that it may change more than 20 years before symptoms in some forms of Alzheimer’s disease.
- In 2025, the FDA cleared the first relevant blood test, while multicenter validation in Japanese participants and distribution of research assays are advancing.
- Challenges remain, including interpretation in asymptomatic people and standardization of cutoff values. p-tau217 supports diagnosis but is not a stand-alone definitive test.
- Earlier identification of risk may provide an opportunity for clinical evaluation and timely intervention.
At present, p-tau217 testing is beginning to be used mainly as a diagnostic aid in medical settings. People concerned about memory loss or other cognitive symptoms should consult a clinician or specialist memory clinic.
When headlines claim that dementia risk can now be determined from blood, it is important to understand what the test measures, what has already been implemented, and what remains under investigation.
References
- 内閣府「共生社会の実現を推進するための認知症基本法」（令和5年法律第65号、2024年1月1日施行） ↩
- Wang Y, Mandelkow E. "Tau in physiology and pathology." Nature Reviews Neuroscience 17: 5–21 (2016) ↩
- Palmqvist S, et al. "Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders." JAMA 324(8): 772–781 (2020) ↩
- Khalafi M, et al. "Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis." Alzheimer's & Dementia (2025) ↩
- Bateman RJ, et al. "Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease." New England Journal of Medicine 367: 795–804 (2012) ↩
- U.S. Food and Drug Administration. "FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease." Press Announcement (May 2025) ↩
- 新潟大学脳研究所「血液バイオマーカー"p-tau217"は脳内病理を高精度に検出し、アルツハイマー病の発症を予測する」プレスリリース（2026年2月13日） ↩
- Ashton NJ, et al. "Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology." JAMA Neurology 81(3): 255–263 (2024) ↩
- 東京都健康長寿医療センター研究所「血漿p-tau217は脳アミロイド蓄積に対して脳脊髄液バイオマーカーと同等の検出精度を示す ― 多施設共同前向き臨床試験で実証 ―」プレスリリース（2026年3月27日） ↩
- シスメックス株式会社「アルツハイマー病関連、血液中のp-Tau217を測定する研究用試薬を発売」ニュースリリース（2026年4月13日） ↩
- Alzforum. "Even With Cognitively Normal Aging, Plasma P-Tau217 Rises." Conference Coverage（2025） ↩
- Mattsson-Carlgren N, et al. "Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials." Neurology ↩
- García-Yagüe AJ, et al. "Hexaraphane as a potential therapeutic strategy for tauopathies." Redox Biology 92, 104107 (2026) ↩
